Product Program year 2025 Source: CMS Open Payments

Lamivudine

Drug Reverse Transcriptase Inhibitor

NDC 60505-3251-6

Open in the dashboard

General payments

$0

0 payments

Research payments

$1,740

41 payments

Through program year 2025, $0 in general payments and $1,740 in research payments were reported against Lamivudine (Reverse Transcriptase Inhibitor).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 Research $606 18
2024 Research $1,134 23

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

24,426

Prescriptions dispensed, refills included

Drug cost

$3,166,437

Paid at the pharmacy, in all

Medicare Part D drugs matched to LAMIVUDINE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Lamivudine Same name 786 14,947 $1,421,526
Lamivudine Hbv Lamivudine Same name 381 6,133 $1,046,501
Lamivudine-Zidovudine Lamivudine/Zidovudine Similar name 211 3,233 $656,870
Epivir Lamivudine Same name 8 113 $41,541

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 287 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
George Therapondos Gastroenterology LA 147 $9,921 None on record
Michael Stuart Internal Medicine LA 145 $15,558 None on record
John English Family Practice CA 139 $20,276 None on record
Ardis Moe Family Practice CA 123 $14,557 None on record
Shobha Joshi Gastroenterology LA 122 $10,591 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 287 with Patron
41 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record